PCM
ZBIO

Prelude Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Prelude Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,645
Closed -$325K – 1581
2026
Q1 		$325K Buy
+16,645
New +$374K 0.02% 679

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Prelude Capital Management's ZBIO Position: Q2 2026 in Review

Prelude Capital Management sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 16,645 shares — an estimated $325K sold.

Prelude Capital Management first reported a position in ZBIO in Q1 2026 and held it in 1 quarter. The position peaked at $325K in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Prelude Capital Management reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 16,645 Zenas BioPharma shares in Q2 2026, an estimated $325K.
  • Prelude Capital Management first reported a position in Zenas BioPharma in Q1 2026 and held it in 1 quarter.
  • Prelude Capital Management's Zenas BioPharma position peaked at $325K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.